Protizinic Acid

Protizinic Acid

SCHEMBL2072946

CC(C(=O)O)c1ccc2c(c1)Cc1cccnc1O2.COc1ccc2c(c1)Sc1ccc(C(C)C(=O)O)cc1N2C

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.63
ABCC4 O15439 1/20 0.63
TP53 P04637 3/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
ALOX12 P18054 1/20 0.37
CASP1 P29466 1/20 0.37
BRCA1 P38398 1/20 0.37
RAB9A P51151 1/20 0.37
CASP7 P55210 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SNCA P37840 3/20 0.36
PTGS2 P35354 4/20 0.36
OPRK1 P41145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Protizinic Acid SCHEMBL29359535 0.80 AKR1C3 (0.54) PTGS1TP53MEN1NPC1ALDH1A1
Protizinic Acid SCHEMBL18309842 0.80 AKR1C3 (0.54) PTGS1TP53MEN1NPC1ALDH1A1
Protizinic Acid SCHEMBL25022 0.80 AKR1C3 (0.54) PTGS1TP53MEN1NPC1ALDH1A1
Pranoprofen SCHEMBL29652156 0.79 PTGS1 (1.00) PTGS1ABCC4MEN1MAPTKMT2A
Pranoprofen SCHEMBL30315839 0.79 PTGS1 (1.00) PTGS1ABCC4MEN1MAPTKMT2A
Pranoprofen SCHEMBL26008 0.79 PTGS1 (1.00) PTGS1ABCC4MEN1MAPTKMT2A
Pranoprofen SCHEMBL25783945 0.79 PTGS1 (1.00) PTGS1ABCC4MEN1MAPTKMT2A
Pranoprofen SCHEMBL30509656 0.79 PTGS1 (1.00) PTGS1ABCC4MEN1MAPTKMT2A
Pranoprofen SCHEMBL29385910 0.79 PTGS1 (1.00) PTGS1ABCC4MEN1MAPTKMT2A
Pranoprofen SCHEMBL5936565 0.79 PTGS1 (1.00) PTGS1ABCC4MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071611-B2 Spirocyclic heterocyclic derivatives and methods of their use ADOLOR CORPORATION (US) 2011-12-06 US disclosed
US-7906646-B2 Spirocyclic heterocyclic derivatives and methods of their use ADOLOR CORPORATION (US) 2011-03-15 US disclosed
US-20100280058-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2010-11-04 US disclosed
US-20100222374-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2010-09-02 US disclosed
US-20100120808-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2010-05-13 US disclosed
US-7638527-B2 Spirocyclic heterocyclic derivatives and methods of their use ADOLOR CORPORATION (US) 2009-12-29 US disclosed
US-20080102031-A1 Spirocyclic Heterocyclic Derivatives And Methods Of Their Use ADOLOR CORPORATION (US) 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222374-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE OPRK1, OPRD1, OPRL1 PTGS1 325/4885ABCC4 2714/4885TP53 4697/4885
US-20080102031-A1 Spirocyclic Heterocyclic Derivatives And Methods Of Their Use OPRK1, OPRD1, OPRL1 PTGS1 325/4885ABCC4 2714/4885TP53 4697/4885
US-20100280058-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE OPRK1, OPRD1, OPRL1 PTGS1 325/4885ABCC4 2714/4885TP53 4697/4885
US-20100120808-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE OPRK1, OPRD1, OPRL1 PTGS1 325/4885ABCC4 2714/4885TP53 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.